Psychedelics have recently grown in scientific interest, among this, there have been promising findings regarding its potential to treat a range of health problems (such as depression, anxiety, PTSD). Despite the growing research interest in psychedelics, there is little research investigating the effects of microdoses: tiny doses that produce sub-hallucinogenic effects. Additionally, there is...
Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table A2. Adjusted ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table B1. Intent-To-Treat (ITT) Analysis for Demoralization Scale (DSII) and PTSD Checklist for DSM-5 (PCL-5). Table B2. Adjusted Intent-To-Treat (ITT)...
In a historic move toward transparency, the U.S. Food and Drug Administration (FDA) on Sept. 4 publicly released its Complete Response Letter (CRL) rejecting the approval of midomafetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD). The letter, sent to Lykos Therapeutics in August 2024, outlines concerns about treatment durability, study design and prior MDMA use among...
Serotonergic psychedelics have shown promise in clinical trials for treating an array of mental health disorders, including depression, anxiety, and post-traumatic stress disorder. Despite these findings, our understanding of how these drugs mechanistically exert their therapeutic effects remains incomplete. While researchers have regularly employed rodent preclinical models to assess such...
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD) og social angstlidelse (SAD), er meget udbredte og reagerer ofte dårligt på konventionel farmakologisk behandling og psykoterapi. Nyere kliniske forsøg har vist, at psykedeliske stoffer og ketamin kan udøve hurtige og vedvarende effekter gennem...
3,4-methelenedioxymethamphetamine (MDMA) can be effective in treating posttraumatic stress disorder (PTSD) in controlled trials, potentially secondary to MDMA’s effects on neural circuits implicated in fear and reward. Although anxiety, stress, and fear-based disorders involve maladaptation of the neural circuits processing fear, threat, and reward, no studies have tested MDMA’s therapeutic...
Ketamine， a non-competitive N-methyl-D-aspartate （NMDA） receptor antagonist， has gained increasing attention for its rapid antidepressant effects in treatment-resistant depression （TRD） and suicidal ideation. Its mechanisms include NMDA receptor blockade， AMPA receptor activation， and upregulation of BDNF/mTOR signaling. Its enantiomers， esketamine and R-ketamine， as well as its metabolites，...
Psychedelic drugs, known for their profound effects on perception, cognition, and emotion, have long captivated scientific, cultural, and therapeutic interest. Following the discovery of LSD’s psychoactive properties in 1943, research surged into its therapeutic potential and the nature of consciousness. However, the integration of psychedelics into the 1960s counterculture led to moral panic,...
Tropane alkaloids and their derivatives represent a diverse class of small molecules with a broad range of therapeutic applications. Many tropanes regulate synaptic levels of neuromodulators by interacting with monoamine transporters such as dopamine (DAT) and serotonin (SERT) transporters. While DAT inhibition plays an important role in the addictive potential of tropanes such as cocaine,...
The potential use of psychedelic-assisted therapy for adolescents with mental illness has sparked both interest and concern. Modern psychedelic research has focused on adults, and adolescents younger than 18 years are typically excluded due to ethical and legal challenges. To explore whether adolescents have been included in 21st century psychedelic research, we conducted a scoping review of...